Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexey Levashkevich

Obstetrics Flint, MI Medical Doctor

NPI 1124140405 CMS profile 278223

1010 N Linden Rd, Flint, MI 48532

Open in the dashboard

General payments

$22,660

194 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexey Levashkevich of Flint, MI is reported in the CMS Open Payments database as having received $22,660 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Obstetrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,694 32
2024 General $3,264 13
2023 General $1,327 11
2022 General $1,749 14
2021 General $202 10
2020 General $1,121 31
2019 General $1,303 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexey Levashkevich
  • Obstetrics median
  • Middle half of Obstetrics
  • National median

In program year 2025, general payments to Alexey Levashkevich were reported at $13,694. Among 649 Obstetrics profiles paid that year, the median was $181 and the middle half received between $61 and $424.

Show as a table
Year Alexey Levashkevich Obstetrics median Middle half National median
2019 $1,303 $177 $60–$381 $163
2020 $1,121 $92 $35–$201 $114
2021 $202 $125 $40–$351 $132
2022 $1,749 $186 $65–$448 $149
2023 $1,327 $183 $61–$451 $160
2024 $3,264 $176 $62–$406 $164
2025 $13,694 $181 $61–$424 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Coloplast Corp $19,632 54 payments
  2. Intuitive Surgical, Inc. $830 25 payments
  3. Medtronic USA, Inc. $549 5 payments
  4. AbbVie, Inc. $218 12 payments
  5. Allergan Inc. $166 15 payments
  6. CooperSurgical, Inc. $131 3 payments
  7. ASCEND Therapeutics US, LLC $127 33 payments
  8. Axonics Modulation Technologies, Inc. $104 5 payments
  9. Medicem Inc. $100 1 payment
  10. Minerva Surgical, Inc $98 2 payments
  11. Other $705 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $15,790 5 payments
  2. Food and Beverage $3,424 158 payments
  3. Travel and Lodging $3,196 13 payments
  4. Gift $219 16 payments
  5. Education $31 2 payments
Products named General payments · program years 2019–2025
  1. Altis $12,874 32 payments
  2. Luja Coude $5,850 1 payment
  3. Da Vinci Surgical System $830 25 payments
  4. INTERSTIM $549 5 payments
  5. FEMALE INCONTINENCE $237 7 payments
  6. Uterine Manipulators & Injectors $105 1 payment
  7. LO LOESTRIN FE $103 8 payments
  8. DILAPAN-S $100 1 payment
  9. ORIAHNN $99 5 payments
  10. Restorelle $98 3 payments
  11. Other $1,538 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

303

Median for Obstetrics & Gynecology: 65

Drug cost

$52,688

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

43.9%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 50 $30,060
Mirabegron Er Mirabegron Brand 39 $18,232
Estradiol Generic 47 $3,163
Oxybutynin Chloride Generic 62 $494
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 33 $297
Oxybutynin Chloride Er Oxybutynin Chloride Brand 11 $242
Ciprofloxacin Hcl Generic 50 $124
Cyclobenzaprine Hcl Generic 11 $78

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$40,853

Medicare's payments for the services billed

Medicare patients

66

Average age 68

Services billed

267

66 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 59%
Diabetes 36%
Depression 30%
Ischemic heart disease 21%
Chronic kidney disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record